Brief: Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Bio Green Med Solution

04/06/2024 13:35

June 4 (Reuters) - Cyclacel Pharmaceuticals Inc
 CYCC.O :
    * CYCLACEL PHARMACEUTICALS: FADRACICLIB DEMONSTRATES
EFFICACY IN
PATIENT-DERIVED COLORECTAL CANCER MODELS AT 2024 ASCO ANNUAL
MEETING

Source text for Eikon:  ID:nGNX5XHl15 
Further company coverage:  CYCC.O 

 ((Reuters.Briefs@thomsonreuters.com;))